Article
Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Apr 2003
Berns Els M J J, Klijn Jan G M, Look Maxime P, Grebenchtchikov Nicolai, Vossen Rolf, Peters Harry, Geurts-Moespot Anneke, Portengen Henk, van Staveren Iris L, Meijer-van Gelder Marion E, Bakker Bert, Sweep Fred C G J, Foekens John A
Abstract excerpt
PURPOSE: In recent studies, we showed that TP53 gene mutation or high levels of cytosolic vascular endothelial growth factor (VEGF) in estrogen receptor (ER)-alpha-positive primary breast tumors predict a poor disease outcome for patients treated with first-line tamoxifen for advanced disease. Mutant TP53 may up-regulate VEGF, whereas, on the other hand, wild-type TP53 may decrease VEGF production. EXPERIMENTAL...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.